Table 4

Odds ratio (95% CI) for functional gastrointestinal disorder phenotype versus controls in polymorphic (heterozygous or homozygous polymorphism) relative to respective wild-type genotypes

IBS-CIBS-DIBS-AltCAP
SLC6A4 (heterozygous or homozygous polymorphism).
α2C Del 322–325 (heterozygous or homozygous polymorphism).
α2A −1291 (C→G) (heterozygous or homozygous polymorphism).
IBS-C, irritable bowel syndrome with predominant constipation; IBS-D, irritable bowel syndrome with predominant diarrhoea; IBS-Alt, irritable bowel syndrome with alternating bowel function; CAP, chronic abdominal pain; NE, non-estimable.
SLC6A4 0.7 (0.4, 1.2)1.0 (0.6, 1.7)0.7 (0.3, 1.4)0.9 (0.3, 2.5)
α2C Del 322–325 2.5 (1.0, 6.3)1.3 (0.5, 3.4)2.2 (0.7, 7.1)0.8 (0.1, 6.8)
α2A −1291 (C→G) 1.7 (0.9, 2.9)1.2 (0.7, 2.0)1.3 (0.6, 2.8)1.2 (0.5, 3.2)
α2A −1291 (C→G) and SLC6A41.1 (0.5, 2.7)1.4 (0.6, 3.2)0.7 (0.2, 2.2)1.2 (0.3, 5.6)
α2C Del 322–325 and SLC6A42.2 (0.4, 12.1)1.3 (0.2, 7.5)1.0 (0.1, 11.7)2.4 (0.2, 32.4)
α2A −1291 (C→G) and α2C Del 322–325NE2.3 (0.3, 16.0)3.3 (0.4, 30.4)NE
α2A −1291 (C→G) and SLC6A4 and α2C Del 322–3254.1 (0.6, 25.8)1.5 (0.2, 12.7)3.5 (0.4, 31.8)NE